Geoffrey Porges
Stock Analyst at SVB Leerink
(1.36)
# 3,356
Out of 4,854 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $23.35 | +139.83% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $29.61 | -32.46% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $9.97 | +903.01% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $493.22 | +72.34% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $54.25 | -11.52% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $290.33 | -25.60% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $189.83 | -28.88% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.23 | -2.05% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $112.46 | -33.31% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $50.47 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $11.26 | -11.19% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.31 | +9,475.49% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $450.50 | -61.15% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $16.19 | +418.84% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $41.20 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.22 | +744.88% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $133.13 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $23.35
Upside: +139.83%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $29.61
Upside: -32.46%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $9.97
Upside: +903.01%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $493.22
Upside: +72.34%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $54.25
Upside: -11.52%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $290.33
Upside: -25.60%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $189.83
Upside: -28.88%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.23
Upside: -2.05%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $112.46
Upside: -33.31%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $50.47
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $11.26
Upside: -11.19%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.31
Upside: +9,475.49%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $450.50
Upside: -61.15%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $16.19
Upside: +418.84%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $41.20
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.22
Upside: +744.88%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $133.13
Upside: -